← Back to Search
Summary Of Presentation From The Targeted Therapy In Lung Cancer Meeting.
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
New pathways are being identified now on a regular basis, and novel agents are being tested in a wide variety of clinical trials for patients with advanced non-small cell lung cancer. Excitement over progress in one area is tempered naturally by disappointing results in other areas. Each year, leading lung cancer experts meet in Santa Monica to discuss the progress in the field of molecularly targeted therapy in non-small cell lung cancer. Annual conferences similar to the one held in Santa Monica serve mainly as a catalyst to promote new ideas and foster active collaboration. We have invited participants to provide very brief succinct summaries of the presentations for this supplement. The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles.
This paper references
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
A. Tolcher (2008)
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Michael Hedvat (2009)
Alterations of the Notch pathway in lung cancer
Britta Westhoff (2009)
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
D. Siemann (2008)
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
Molecular analysis identifies a subset of non-small cell lung cancer patients with differential sensitivity to histone deacetylase inhibitor/epidermal growth factor receptor tyrosine kinase treatment
R M Jotte (2010)
A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)
V. Papadimitrakopoulou (2007)
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
P. LoRusso (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
K. Gelmon (2011)
A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.
J. von Pawel (2010)
Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
C. Bondzi (2000)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo.
K. West (2004)
Histone deacetylases and cancer: causes and therapies
P. Marks (2001)
Purine-scaffold Hsp90 inhibitors.
Tony Taldone (2009)
The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage
D. Chen (2007)
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
D. Spigel (2010)
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
L. Krug (2000)
Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer
T. Stinchcombe (2008)
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
L. Sequist (2010)
Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).
M. Socinski (2010)
Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).
M. O'Brien (2010)
EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells
A M Gobin (2008)
Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.
A. Jimeno (2010)
Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.
J. Desai (2010)
Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids
J. He (2007)
412 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors
Q. Chu (2010)
Randomized double-blind placebocontrolled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer
S M Lee (2009)
Smac mimetics and TNFalpha: a dangerous liaison?
Hao Wu (2007)
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage nonsmall-cell lung cancer
L Paz-Ares (2006)
ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.
M. Ellis (2010)
Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial
N. Ready (2010)
Kinesin motor proteins as targets for cancer therapy
D. Huszar (2009)
Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome
L. Stabile (2010)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
L. Sequist (2011)
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
T. Lynch (2010)
Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
A. Ricart (2008)
X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists
E. Varfolomeev (2009)
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
L. Gandhi (2011)
A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
K. Chi (2008)
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
K. Kelly (2008)
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.
M. Kinch (2003)
The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.
Raga Krishnakumar (2010)
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
A. Tolcher (2009)
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
M. Reck (2009)
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
A. Chiappori (2010)
Expression and mutational analysis of MET in human solid cancers
P. Ma (2008)
EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
J. Lee (2010)
Hunting the Hedgehog Pathway
G. Weiss (2010)
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
L. Horn (2009)
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
U. McDermott (2009)
Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer
C S Karapetis (2010)
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
K. Sugahara (2010)
EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation*
L. Faoro (2010)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
M. Jordan (2005)
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
J. Vansteenkiste (2007)
Estrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomized controlled trial
R T Chlebowski (2009)
A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
E. Rowinsky (2007)
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.
H. Yu (1999)
Activity of IPI504 , a novel heatshock protein 90 inhibitor , in patients with molecularly defined non - small - cell lung cancer
LV Sequist (2010)
Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies
C. Dumontet (2009)
Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.
P. Jänne (2010)
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
K. Price (2010)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
R. Pirker (2009)
Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise.
S. Baylin (2000)
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.
J. Tsurutani (2006)
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
E. Kawata (2008)
Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation.
Yubin Zhang (2006)
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
R. Herbst (2010)
Tobacco Carcinogen-Induced Cellular Transformation Increases Activation of the Phosphatidylinositol 3′-Kinase/Akt Pathway in Vitro and in Vivo
K. West (2004)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
J. Engelman (2007)
Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
N. Lindor (2001)
Targeted manipulation of apoptosis in cancer treatment.
J. Call (2008)
Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2
N. Rizvi (2008)
Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
L. Liu (2011)
Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.
V. Potiron (2007)
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
S. Ramalingam (2010)
Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer.
K. Hibi (1991)
IAP antagonists: promising candidates for cancer therapy.
R. Mannhold (2010)
Met, metastasis, motility and more
C. Birchmeier (2003)
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
K. Shibuya (2007)
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
L. Sequist (2010)
Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer
N. Choong (2008)
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
R. Herbst (2005)
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
R. Ramlau (2008)
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.
D. Bissett (2005)
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
J. Tang (2006)
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Laura Schmidt (1999)
Stereotactic body radiation therapy for inoperable early stage lung cancer.
R. Timmerman (2010)
Vorinostat increases carboplatin and paclitaxel activity in non‐small cell lung cancer cells
T. Owonikoko (2010)
Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines.
C. Papadimitriou (1995)
Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
D. Talbot (2010)
Safety and pharmacokinetics of first-line AMG 479 (Mab to IGF1R) or AMG 102 (Mab to HGF/SF) with platinum-based chemotherapy in extensive-stage small cell lung cancer (SCLC)
P Lorigan (2010)
First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.
H. Burris (2010)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
David A. Eberhard (2005)
C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma
H. Kindler (2007)
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
S. Laurie (2008)
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
L. Marek (2009)
Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel
P. Sève (2005)
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
G. Goss (2010)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
J. Bean (2007)
GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
A. Bai (2010)
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
D. V. Von Hoff (2009)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
T. Mitsudomi (2010)
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
A. Tarhini (2010)
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
G. Dy (2005)
Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials
P. Paik (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
J. Weiss (2010)
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
M. Arcila (2011)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
A. Sandler (2006)
Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists1
A. Wesa (2008)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
G. Giaccone (2004)
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network
D. Spigel (2007)
Targeting the dynamic HSP90 complex in cancer
J. Trepel (2010)
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
D. Karp (2009)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
C. Zhou (2011)
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
P. Rous (1911)
BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer
E. Powell (2008)
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
V. Macaulay (2011)
Preferential expression of c-kit protooncogene transcripts in small cell lung cancer.
Y. Sekido (1991)
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
A. Tsao (2007)
Neratinib , an irreversible panErbB receptor tyrosine kinase inhibitor : results of a phase II trial in patients with advanced non - small - cell lung cancer
LV Sequist (2010)
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.
N. Desai (2009)
A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST).
A. Tolcher (2009)
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
M. Maemondo (2010)
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
M. McKeage (2008)
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
A. Das (2006)
Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.
C. Milross (1996)
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
Q. Chang (2008)
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.
B. Balsara (2004)
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
S. Williamson (2005)
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
D. Stéhelin (1976)
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
S. Ramalingam (2007)
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer
T. Seiwert (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
U. Gatzemeier (2007)
Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics
Kristi E Allen (2010)
Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Y. Janjigian (2011)
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC.
G. Blumenthal (2010)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
R. Herbst (2004)
Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
D. Spigel (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer
R. Digumarti (2011)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
P. Comoglio (2008)
Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors*
R. Noberini (2008)
A phase 1 study of IPI-926, an inhibitor of the Hedgehog pathway, in patients with advanced or metastatic solid tumors
C Rudin (2010)
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
L. Schmidt (1997)
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Rachel M. A. Linger (2010)
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
G. Blumenschein (2008)
A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.
J. Baselga (2010)
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.
M. Scartozzi (2010)
Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.
U. Swami (2010)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L. Kwak (2010)
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
C. Gridelli (2010)
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
G. Rustin (2010)
In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor.
Z. Dikmen (2005)
Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179.
A. Oza (2009)
Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features
C. Rudin (2011)
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
R. Ramlau (2008)
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming
D. Atanackovic (2008)
Shared and separate functions of polo-like kinases and aurora kinases in cancer
S. Lens (2010)
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
N. Altorki (2010)
Molecular cloning of a new transforming gene from a chemically transformed human cell line
C. Cooper (1984)
A randomized phase II study of paclitaxel and carboplatin Ϯ bevacizumab Ϯ dulanermin in non-small cell lung cancer
F H Blackhall (2010)
Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study
G Scagliotti (2010)
Phase II study of the efficacy and safety of intravenous (IV) AVE005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum-and erlotinib-resistant adenocarcinoma of the lung
E Massarelli (2007)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein: A phase II clinical trial
O. Altundag (2005)
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
C. L. Hann (2008)
This paper is referenced by
Year-in-Review of Lung Cancer
J. Son (2012)
Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
C. Usul Afsar (2015)
Synergistic interactions of targeted therapy within signal transduction pathways
S. Glaysher (2012)
Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Ina Hohensee (2013)